Galmed Pharmaceuticals Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLMD research report →
Companywww.galmedpharma.com
Galmed Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
- CEO
- Allen Baharaff
- IPO
- 2014
- Employees
- 3
- HQ
- Ramat Gan, IL
Price Chart
Valuation
- Market Cap
- $3.31M
- P/E
- -0.39
- P/S
- 0.00
- P/B
- 0.25
- EV/EBITDA
- 0.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -57.04%
- ROIC
- -53.92%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-10,309,000 · -37.14%
- EPS
- $-2.39 · 70.42%
- Op Income
- $-8,510,000
- FCF YoY
- -7.40%
Performance & Tape
- 52W High
- $2.34
- 52W Low
- $0.41
- 50D MA
- $0.62
- 200D MA
- $0.98
- Beta
- 0.62
- Avg Volume
- 3.10M
Get TickerSpark's AI analysis on GLMD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GLMD Coverage
We haven't published any research on GLMD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GLMD Report →